9-Deoxy-6,9.alpha.-epoxymethano-PG C-1 alcohols
    51.
    发明授权
    9-Deoxy-6,9.alpha.-epoxymethano-PG C-1 alcohols 失效
    9-脱氧-6,9α-环氧甲烷-PG C-1醇

    公开(公告)号:US4206303A

    公开(公告)日:1980-06-03

    申请号:US940921

    申请日:1978-09-11

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    CPC分类号: C07C405/0041 C07D311/94

    摘要: Processes for preparing prostacyclin analogs which are 9-deoxy-6,9-epoxymethano derivatives of prostaglandin F.sub.1.alpha. -type compounds, illustrated, for example, by a compound of the formula ##STR1## wherein .about. indicates alpha or beta configuration; including the products and intermediates produced therein, said products having pharmacological utility.

    摘要翻译: 制备作为前列腺素F1α型化合物的9-脱氧-6,9-环氧甲烷衍生物的前列环素类似物的方法,例如由下式表示的化合物,其中DIFFERENCE表示α或β构型; 包括其中生产的产品和中间体,所述产品具有药理实用性。

    Enlarged-hetero-ring prostacyclin analogs
    52.
    发明授权
    Enlarged-hetero-ring prostacyclin analogs 失效
    放大杂环前列环素类似物

    公开(公告)号:US4202971A

    公开(公告)日:1980-05-13

    申请号:US12263

    申请日:1979-02-15

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    IPC分类号: C07C405/00 C07D311/94

    摘要: Prostaglandin (PG.sub.1) derivatives having (1) a 6-keto feature, together with a 9-deoxy-9-hydroxymethyl feature for example ##STR1## or (2) a 9-deoxy-6,9-epoxymethano feature together with a 5-halo or 6-hydroxy feature, for example ##STR2## or a 5,6-didehydro feature, for example in an enol ether of the formula ##STR3## said derivatives having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.

    摘要翻译: 前体前列腺素(PG1)衍生物具有(1)6-酮特征,以及9-脱氧-9-羟甲基特征,例如(IMAGE)或(2)9-脱氧-6,9-环氧甲烷特征以及5 - 卤代或6-羟基特征,例如 或5,6-二脱水特征,例如在式(I)的烯醇醚中,所述衍生物具有药理学活性。 公开了制备它们的方法和合适的中间体。

    Enlarged-hetero-ring prostacyclin analogs
    53.
    发明授权
    Enlarged-hetero-ring prostacyclin analogs 失效
    放大杂环前列环素类似物

    公开(公告)号:US4200739A

    公开(公告)日:1980-04-29

    申请号:US935392

    申请日:1978-08-21

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    CPC分类号: C07C405/00 C07D311/94

    摘要: Prostaglandin (PG.sub.1) derivatives having (1) a 6-keto feature, together with a 9-deoxy-9-hydroxymethyl feature for example ##STR1## or (2) a 9-deoxy-6,9-epoxymethano feature together with a 5-halo or 6-hydroxy feature, for example ##STR2## or a 5,6-didehydro feature, for example in an enol ether of the formula ##STR3## said derivatives having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.

    摘要翻译: 前体前列腺素(PG1)衍生物具有(1)6-酮特征,以及9-脱氧-9-羟甲基特征,例如(IMAGE)或(2)9-脱氧-6,9-环氧甲烷特征以及5 - 卤代或6-羟基特征,例如或5,6-脱水特征,例如在式(I)的烯醇醚中,所述衍生物具有药理活性。 公开了制备它们的方法和合适的中间体。

    Enlarged-hetero-ring prostacyclin analogs
    54.
    发明授权
    Enlarged-hetero-ring prostacyclin analogs 失效
    放大杂环前列环素类似物

    公开(公告)号:US4124599A

    公开(公告)日:1978-11-07

    申请号:US819941

    申请日:1977-07-28

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    摘要: Prostaglandin (PG.sub.1) derivatives having (1) a 6-keto feature, together with a 9-deoxy-9-hydroxymethyl feature for example ##STR1## or (2) a 9-deoxy-6,9-epoxymethano feature together with a 5-halo or 6-hydroxy feature, for example ##STR2## or a 5,6-didehydro feature, for example in an enol ether of the formula ##STR3## said derivatives having pharmacological activity. Processess for preparing them and the appropriate intermediates are disclosed.

    摘要翻译: 前体前列腺素(PG1)衍生物具有(1)6-酮特征,以及9-脱氧-9-羟甲基特征,例如(IMAGE)或(2)9-脱氧-6,9-环氧甲烷特征以及5 - 卤代或6-羟基特征,例如或5,6-脱水特征,例如在式(I)的烯醇醚中,所述衍生物具有药理活性。 公开了制备它们的方法和合适的中间体。

    4,5-Didehydro-6-methoxy-2-arylmethoxymethyl-4.alpha.-tetrahydropyranacet
ic acid alkyl esters
    56.
    发明授权
    4,5-Didehydro-6-methoxy-2-arylmethoxymethyl-4.alpha.-tetrahydropyranacet ic acid alkyl esters 失效
    4,5-二脱氢-6-甲氧基-2-芳基甲氧基甲基-4 {60-四氢吡喃乙酸烷基酯

    公开(公告)号:US4100178A

    公开(公告)日:1978-07-11

    申请号:US784178

    申请日:1977-04-04

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    摘要: The present specification provides novel intermediates and novel processes for the synthesis of Thromboxane B.sub.2 11a-homo-11a-oxa-PGF.sub.2.alpha.), its 15-epimer, and various carboxyl derivatives thereof. In particular, there are disclosed various bicyclic tetrahydrofuran-containing lactones useful in the above processes, and corresponding acyclic lactones.

    摘要翻译: 本说明书提供了用于合成血栓烷B211a-homa-11a-oxa-PGF2α),其15-差向异构体及其各种羧基衍生物的新型中间体和新方法。 特别地,公开了可用于上述方法的各种双环四氢呋喃内酯,以及相应的无环内酯。

    4,5-Didehydro-6-hydrox
y-2-arylmethoxymethyl-4.alpha.-tetrahydropyranacetic acid alkyl esters
    57.
    发明授权
    4,5-Didehydro-6-hydrox y-2-arylmethoxymethyl-4.alpha.-tetrahydropyranacetic acid alkyl esters 失效
    4,5-二脱氢-6-羟基-2-芳基甲氧基甲基-4 {60-四氢吡喃乙酸烷基酯

    公开(公告)号:US4100177A

    公开(公告)日:1978-07-11

    申请号:US784175

    申请日:1977-04-04

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    摘要: The present specification provides novel intermediates and novel processes for the synthesis of Thromboxane B.sub.2 11a-homo-11a-oxa-PGF.sub.2.alpha.), its 15-epimer, and various carboxyl derivatives thereof. In particular, there are disclosed various bicyclic tetrahydrofuran-containing lactones useful in the above processes, and corresponding acyclic lactones.

    摘要翻译: 本说明书提供了用于合成血栓烷B211a-homa-11a-oxa-PGF2α),其15-差向异构体及其各种羧基衍生物的新型中间体和新方法。 特别地,公开了可用于上述方法的各种双环四氢呋喃内酯,以及相应的无环内酯。

    4,5-Didehydro-6-hydroxy-2.beta.-arylm
ethoxymethyl-4.alpha.-tetrahydropyranacetic acids
    58.
    发明授权
    4,5-Didehydro-6-hydroxy-2.beta.-arylm ethoxymethyl-4.alpha.-tetrahydropyranacetic acids 失效
    4,5-二脱氢-6-羟基-2 {62-芳基甲氧基甲基-4 {60-四氢吡喃乙酸

    公开(公告)号:US4100176A

    公开(公告)日:1978-07-11

    申请号:US784476

    申请日:1977-04-04

    申请人: Robert C. Kelly

    发明人: Robert C. Kelly

    摘要: The present specification provides novel intermediates and novel processes for the synthesis of Thromboxane B.sub.2 11a-homo-11a-oxa-PGF.sub.2a), its 15-epimer, and various carboxyl derivatives thereof. In particular, there are disclosed various bicyclic tetrahydrofuran-containing lactones useful in the above processes, and corresponding acyclic lactones.

    摘要翻译: 本说明书提供了新型的中间体和用于合成血栓烷B2aa-homa-11a-oxa-PGF2a),其15-差向异构体及其各种羧基衍生物的新方法。 特别地,公开了可用于上述方法的各种双环四氢呋喃内酯,以及相应的无环内酯。